



Discover a novel diet aimed at supporting diabetic patients through weight loss and more. Meet **GLYCOADVANCED™**, a diet formulated with an **INCREASED NUTRIENT-TO-CALORIE RATIO** and designed to enable **SAFE CALORIC RESTRICTION IN OVERWEIGHT DIABETIC CATS**, with **REDUCED STARCH CONTENT** to promote glycemic control and improve the likelihood of diabetic remission.

OBJECTIVE

The purpose of this study was to assess the **IMPACT OF CALORIC RESTRICTION WITH A PURPOSE-FORMULATED DIABETIC DIET** on remission and glycemic control in overweight diabetic cats.

TRIAL PROTOCOL

A dual-center, prospective and randomized control trial involving overweight (body condition score [BCS] $\geq 6/9$), client-owned, insulin-treated cats with diabetes mellitus (DM).

STUDY SITES

- University of Copenhagen, Denmark
- Royal Veterinary College, London, UK

SELECTION CRITERIA

INCLUSION CRITERIA AT SCREENING

- ✓ Adult cat (>1 year of age) with BCS $\geq 6/9$
- ✓ Duration of DM >4 weeks and <24 months
- ✓ Treated with protamine zinc insulin for at least 3 weeks
- ✓ If previously in remission, relapse and insulin dependent >1 month
- ✓ Not deemed to be repeatedly cycling between remission and relapse
- ✓ Not deemed to be at risk of complications (e.g. diabetic ketoacidosis (DKA), hypoglycemia)
- ✓ No glucocorticoid treatment within 4 weeks prior to diagnosis or between recruitment and inclusion
- ✓ No concurrent uncontrolled hyperthyroidism, pancreatitis or gastrointestinal signs
- ✓ No evidence of liver disease, adrenal disease, hypersomatotropism or food intolerance
- ✓ If present, chronic kidney disease IRIS stage ≤ 2


EXCLUSION CRITERIA POST INCLUSION

- ✗ Cat not eating the novel diet
- ✗ Cat is fearful or anxious with handling
- ✗ Lacking owner compliance
- ✗ Severe clinical signs of illness

STUDY DESIGN

- Both groups were fed **ROYAL CANIN® GLYCOADVANCED™**, a diet purpose-formulated to support the regulation of blood glucose and to be suitable for weight reduction and weight maintenance in cats with diabetes.
- The control group was fed for weight maintenance, and the intervention group underwent caloric restriction aiming to achieve weight reduction of 2% body weight weekly.

STUDY DESIGN (CONTINUED)



- Inclusion visit (V0) at week -1; full clinical examination by participating veterinarian, including hematology, biochemistry, T4, fPLI, IGF-1 and urine analysis, and completion of diabetic clinical score (DCS; presence of clinical signs related to diabetes mellitus)¹ and quality of life questionnaires² by owner.
- Cats randomized to control or intervention groups, both fed ROYAL CANIN® GLYCOADVANCED™ as wet, dry or mixed, based on cat and owner preference.
- Maximum 10% of daily energy allocation as pre-approved treat options.
- One-week food adaptation where both groups fed for maintenance of body weight, followed by 12-week intervention period:
 - Control group fed for maintenance of initial body weight.
 - Intervention group fed for restricted caloric allocation with a target of 2% weekly weight reduction.
- Calorie allocation revised weekly based on at-home weight checks using electronic cat scales provided to all owners.
- Revisit consults at weeks 4 (V1) and 8 (V2) by principle investigator or cat's own veterinarian and 12 (V3) by principal investigator; clinical examination as per inclusion visit with the exception of IGF-1.

OUTCOME	ASSESSMENT
DIABETIC REMISSION	Defined as either: <ul style="list-style-type: none"> a) Serum fructosamine <350 µmol/L (6.31 mg/dL) or blood glucose <7.5 mmol/L (135 mg/dL), measured ≥ 28 days after withdrawing insulin; or b) Continuing cessation of insulin therapy for at least 3 months after stopping, with absence of clinical signs of DM
WEIGHT REDUCTION	<ul style="list-style-type: none"> Weighed weekly at home Body and muscle condition scoring by veterinarians at weeks 1, 4, 8 and 12 using standardized scoring systems
GLYCEMIC CONTROL	<ul style="list-style-type: none"> Defined by the DCS, insulin dose, serum fructosamine concentration, glycemic variability (GV; calculated as the standard deviation [SD] of blood glucose curve readings) and quality of life 12-hour blood glucose curves at home at weeks 4, 8 and 12, and 1-2 weeks after any insulin adjustment
SAFETY	<ul style="list-style-type: none"> Abnormal physical examination findings, clinically relevant laboratory abnormalities, or other relevant clinical observations were recorded

References: 1. Niessen SJM, Bjornvad C, Church DB, et al. Agreeing Language in Veterinary Endocrinology (ALIVE): Diabetes mellitus - a modified Delphi-method-based system to create consensus disease definitions. *Vet J*. 2022;289:105910. 2. Niessen SJ, Powney S, Guitian J, et al. Evaluation of a quality-of-life tool for cats with diabetes mellitus. *J Vet Int Med*. 2010;24:1098-1105.


Effect of 12-week, intentional caloric restriction, using a novel veterinary diabetic diet suitable for weight reduction, on remission and glycemic control in overweight, insulin-treated diabetic cats: a dual-center, prospective and randomized control trial.

TRIAL RESULTS

CATS


- 72 overweight, client-owned cats (BCS $\geq 6/9$), median body weight 13.2 lb (9-23.6 lb)
- Median age 11 years (3-18 years), all spayed/neutered, predominantly domestic shorthair
- 69% cats had BCS 6/9-7/9 and 31% had BCS 8/9-9/9

REMISSION



WEIGHT REDUCTION

By week 12, cats fed for caloric restriction had lost on average 7.2% of initial body weight, compared with 2.7% in cats fed for weight maintenance ($P<0.001$).




GLYCEMIC CONTROL

Even for cats that did not achieve remission, those fed for caloric restriction **ACHIEVED GREATER GLYCEMIC CONTROL AND A REDUCED INSULIN DOSE** compared with cats fed for weight maintenance.


In cats that did not achieve remission by week 12:

- Insulin dose decreased by 36% in cats that underwent caloric restriction[†]
- Glycemic variability decreased by 45% in cats that underwent caloric restriction[‡]

(A)



(B)



ADDITIONAL RESULTS

- The Diabetic Quality of Life score improved over the 12-week period in both groups of cats, with no difference between groups.**
- Caloric allocation in the caloric restriction group was on average 60% of maintenance energy requirements, resulting in well-tolerated weight reduction with no cats developing DKA or hepatic lipidosis.
- Remission was more closely associated with the degree of caloric restriction than the rate of weight loss, and most cats that entered remission did so in the first 6 weeks. Proportion of wet diet consumed, body weight change during the intervention, age and sex did not affect the likelihood of achieving remission.

CONCLUSION AND CLINICAL RELEVANCE

- Intentional caloric restriction with ROYAL CANIN® GLYCOADVANCED™ improves the likelihood of diabetic remission, improves regulation of blood glucose levels and promotes healthy weight when fed as part of a veterinary diabetic management program in combination with medical therapy.
- Energy intake was significantly restricted in the caloric restriction group and feeding a standard diet under such caloric restriction could result in essential nutrient deficiencies; ROYAL CANIN® GLYCOADVANCED™ is purpose-formulated with an increased nutrient to caloric ratio for safe use during caloric restriction in diabetic cats.

[†]Compared with 28% increase in cats fed for weight maintenance ($P<0.01$).

[‡]Compared with 7% decrease in cats fed for weight maintenance ($P<0.05$).